Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/177709
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJimenez Guiu, Xavier-
dc.contributor.authorHuici Sánchez, Malka-
dc.contributor.authorRomera Villegas, Antonio-
dc.contributor.authorIzquierdo Miranda, Alexandre-
dc.contributor.authorSancho Cerro, Ana-
dc.contributor.authorVila Coll, Ramón-
dc.date.accessioned2021-05-27T09:46:04Z-
dc.date.available2021-05-27T09:46:04Z-
dc.date.issued2021-05-01-
dc.identifier.urihttp://hdl.handle.net/2445/177709-
dc.description.abstractBackground: Venous thromboembolic events have been one of the main causes of mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia. The aim of our study was to describe the prevalence of deep vein thrombosis (DVT) in noncritically ill patients with COVID-19 pneumonia and correlate such observations with the thromboprophylaxis received. Methods: We performed a prospective cohort study of 67 patients admitted to the hospital for COVID-19 pneumonia. The diagnosis was confirmed using polymerase chain reaction testing of nasopharyngeal specimens. The deep veins were examined using compression duplex ultrasonography with the transducer on B-mode. The patients were separated into two groups for statistical analysis: those receiving low-molecular-weight heparin prophylaxis and those receiving intermediate or complete anticoagulation treatment. Risk analysis and logistic regression were performed. Results: Of the 67 patients, 57 were included in the present study after applying the inclusion and exclusion criteria; 49.1% were women, and the patient mean age was 71.3 years. All 57 patients had undergone compression duplex ultrasonography. Of these 57 patients, 6 were diagnosed with DVT, for an in-hospital rate of DVT in patients with COVID-19 pneumonia of 10.5%. All the patients who had presented with DVT had been receiving low-molecular-weight heparin prophylaxis. The patients receiving prophylactic anticoagulation treatment had a greater risk of DVT (16.21%; 95% confidence interval, 0.04-0.28; P = .056) compared with those receiving intermediate or complete anticoagulation treatment. We also found a protective factor for DVT in the intermediate or complete anticoagulation treatment group (odds ratio, 0.19; 95% confidence interval, 0.08-0.46; P < .05). Conclusions: Noncritically ill, hospitalized patients with COVID-19 pneumonia have a high risk of DVT despite receipt of correct, standard thromboprophylaxis.-
dc.format.extent6 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier Inc.-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.jvsv.2020.08.028-
dc.relation.ispartofJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, vol. 9, num. 3, p. 592-596-
dc.relation.urihttps://doi.org/10.1016/j.jvsv.2020.08.028-
dc.rights(c) Society for Vascular Surgery, 2021-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCOVID-19-
dc.subject.classificationTromboflebitis-
dc.subject.otherCOVID-19-
dc.subject.otherThrombophlebitis-
dc.titleDeep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-05-26T13:50:41Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32911110-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Deep vein thrombosis in noncritically ill patients with coronavirus.pdf179.19 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.